{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:56:26Z","timestamp":1790751386454,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient\n                      <jats:italic>in vivo<\/jats:italic>\n                      delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through rational capsid design. This was achieved by site-specifically inserting the high-affinity Clec9a-targeting peptide CBP-12, optimizing its flanking sequences, and introducing T491V\/S662V gain-of-function mutations to synergistically enhance DC transduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The resulting vector, AAV2-mut-Peptide2, showed significantly improved tropism for and gene delivery efficiency to cross-presenting cDC1s\n                      <jats:italic>in vivo<\/jats:italic>\n                      . In murine models of hepatocellular carcinoma, vaccination with this platform, encoding either a model antigen (OVA) or the endogenous tumor-associated antigen GPC3, elicited a potent antigen-specific CD8+ T cell response. This response was characterized by a substantial increase in tumor-infiltrating lymphocytes, enhanced production of key effector cytokines, and consequently, potent suppression of tumor growth.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1932907","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:50Z","timestamp":1790748350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin","family":"Wei","sequence":"first","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Joint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Qi","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Qiu","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wu","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutang","family":"Wei","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Luo","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Shi","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Liu","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Yang","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengke","family":"Bao","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, The First Affiliated Hospital of Henan University","place":["Kaifeng, Henan, China"]},{"name":"Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00455-x","article-title":"Regulation of T cell immunity by dendritic cells","volume":"106","author":"Lanzavecchia","year":"2001","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","article-title":"Future considerations for the mRNA-lipid nanoparticle vaccine platform","volume":"48","author":"Igy\u00e1rt\u00f3","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature07750","article-title":"Identification of a dendritic cell receptor that couples sensing of necrosis to immunity","volume":"458","author":"Sancho","year":"2009","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101176","article-title":"Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype","volume":"187","author":"Lahoud","year":"2011","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41541-025-01084-2","article-title":"Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials","volume":"10","author":"Hussain","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56406","article-title":"Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk\/IL-21 axis","volume":"11","author":"Gou","year":"2021","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8(+) T cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161598","article-title":"Directly injected lentiviral vector-based T cell vaccine protects mice against acute and chronic viral infection","volume":"7","author":"Tada","year":"2022","journal-title":"JCI Insight"},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.07.004","article-title":"Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity","volume":"13","author":"Wu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117010","article-title":"Adeno-associated viral vectors deliver gene vaccines","volume":"281","author":"Wei","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","article-title":"An evolved AAV variant enables efficient genetic engineering of murine T cells","volume":"186","author":"Nyberg","year":"2023","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.02.009","article-title":"Pre-arrayed pan-AAV peptide display libraries for rapid single-round screening","volume":"28","author":"B\u00f6rner","year":"2020","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101143","article-title":"Multiparametric domain insertional profiling of adeno-associated virus VP1","volume":"31","author":"Hoffmann","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00730-25","article-title":"Teaching an old vector new tricks: the surprising versatility of AAV vaccines","volume":"99","author":"Winston","year":"2025","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01343-6","article-title":"Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection","volume":"9","author":"Wang","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992762","article-title":"Therapeutic strategies for gastric cancer targeting immune cells: Future directions","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.74","article-title":"Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy","volume":"92","author":"Pandya","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.10.001","article-title":"An engineered AAV6-based vaccine induces high cytolytic anti-tumor activity by directly targeting DCs and improves ag presentation","volume":"15","author":"Krotova","year":"2019","journal-title":"Mol Ther Oncolytics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:05:51Z","timestamp":1790748351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1932907"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932907","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1932907"}}